Wai Yuen Tong Medicine Holdings revenue falls 6.9% with profit down 88.2%
Wai Yuen Tong Medicine Holdings Limited reported a 6.9% decrease in revenue to HK$322.8 million for the six months ending September 30, 2025. Gross profit fell by 9.2% to HK$165.3 million, and profit attributable to owners dropped 88.2% to HK$2.8 million. Earnings per share decreased to 0.25 HK cents from 2.10 HK cents. The company's net asset value was HK$1,181.5 million, with cash and cash equivalents at HK$121.2 million. The company focuses on Chinese pharmaceutical and health food products, mainly in Mainland China and Hong Kong.
Wai Yuen Tong Medicine Holdings Limited reported revenue of HK$322.8 million for the six months ended 30 September 2025, a decrease of 6.9% compared to HK$346.8 million in the same period last year. Gross profit declined by 9.2% to HK$165.3 million. Profit attributable to owners of the parent fell 88.2% to HK$2.8 million. Basic and diluted earnings per share were 0.25 HK cents, compared to 2.10 HK cents previously. As of 30 September 2025, the Group’s net asset value was HK$1,181.5 million and cash and cash equivalents stood at HK$121.2 million. The principal activities during the period included the production and sale of Chinese pharmaceutical and health food products, provision of Traditional Chinese Medicine services, and management and promotion services, mainly in Mainland China and Hong Kong. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Wai Yuen Tong Medicine Holdings Limited published the original content used to generate this news brief via via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20251124-11926696), on November 24, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)
